Midkine (MDK) in cancer and drug resistance: from inflammation to therapy
Abstract Midkine (MDK) is a heparin-binding growth factor implicated in the pathogenesis of various diseases, including cancer, chronic inflammation, and multidrug resistance (MDR). While its expression is minimal in adult tissues, it becomes markedly elevated during embryogenesis and in response to...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02941-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218409431662592 |
|---|---|
| author | Berna Yıldırım Kudret Kulak Ayhan Bilir |
| author_facet | Berna Yıldırım Kudret Kulak Ayhan Bilir |
| author_sort | Berna Yıldırım |
| collection | DOAJ |
| description | Abstract Midkine (MDK) is a heparin-binding growth factor implicated in the pathogenesis of various diseases, including cancer, chronic inflammation, and multidrug resistance (MDR). While its expression is minimal in adult tissues, it becomes markedly elevated during embryogenesis and in response to injury, infection, or hypoxia. MDK modulates inflammatory responses by recruiting immune cells and enhancing proinflammatory cytokine production. In oncogenesis, it promotes tumor proliferation, angiogenesis, epithelial-to-mesenchymal transition (EMT), and therapeutic resistance. Elevated MDK levels are frequently associated with aggressive tumor behavior and poor clinical outcomes. This review synthesizes current knowledge on MDK’s expression profiles, molecular mechanisms, and functional roles across pathological conditions. It also discusses MDK’s emerging value as a diagnostic and prognostic biomarker, and highlights recent advances in therapeutic strategies including small molecule inhibitors, RNA-based approaches, and receptor-blocking peptides. Overall, MDK represents a promising target for future personalized therapies, although further preclinical and clinical validation is warranted to confirm its translational potential. |
| format | Article |
| id | doaj-art-b512f80a8a5443a386fd8ac60b642d16 |
| institution | OA Journals |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-b512f80a8a5443a386fd8ac60b642d162025-08-20T02:07:45ZengSpringerDiscover Oncology2730-60112025-06-0116111910.1007/s12672-025-02941-1Midkine (MDK) in cancer and drug resistance: from inflammation to therapyBerna Yıldırım0Kudret Kulak1Ayhan Bilir2Department of Histology and Embryology, Faculty of Medicine, İstanbul Atlas UniversityDepartment of Pediatrics, Faculty of Medicine, İstanbul Atlas UniversityDepartment of Histology and Embryology, Faculty of Medicine, İstanbul Atlas UniversityAbstract Midkine (MDK) is a heparin-binding growth factor implicated in the pathogenesis of various diseases, including cancer, chronic inflammation, and multidrug resistance (MDR). While its expression is minimal in adult tissues, it becomes markedly elevated during embryogenesis and in response to injury, infection, or hypoxia. MDK modulates inflammatory responses by recruiting immune cells and enhancing proinflammatory cytokine production. In oncogenesis, it promotes tumor proliferation, angiogenesis, epithelial-to-mesenchymal transition (EMT), and therapeutic resistance. Elevated MDK levels are frequently associated with aggressive tumor behavior and poor clinical outcomes. This review synthesizes current knowledge on MDK’s expression profiles, molecular mechanisms, and functional roles across pathological conditions. It also discusses MDK’s emerging value as a diagnostic and prognostic biomarker, and highlights recent advances in therapeutic strategies including small molecule inhibitors, RNA-based approaches, and receptor-blocking peptides. Overall, MDK represents a promising target for future personalized therapies, although further preclinical and clinical validation is warranted to confirm its translational potential.https://doi.org/10.1007/s12672-025-02941-1Midkine (MDK)Multidrug resistanceInflammatory diseasesCancer |
| spellingShingle | Berna Yıldırım Kudret Kulak Ayhan Bilir Midkine (MDK) in cancer and drug resistance: from inflammation to therapy Discover Oncology Midkine (MDK) Multidrug resistance Inflammatory diseases Cancer |
| title | Midkine (MDK) in cancer and drug resistance: from inflammation to therapy |
| title_full | Midkine (MDK) in cancer and drug resistance: from inflammation to therapy |
| title_fullStr | Midkine (MDK) in cancer and drug resistance: from inflammation to therapy |
| title_full_unstemmed | Midkine (MDK) in cancer and drug resistance: from inflammation to therapy |
| title_short | Midkine (MDK) in cancer and drug resistance: from inflammation to therapy |
| title_sort | midkine mdk in cancer and drug resistance from inflammation to therapy |
| topic | Midkine (MDK) Multidrug resistance Inflammatory diseases Cancer |
| url | https://doi.org/10.1007/s12672-025-02941-1 |
| work_keys_str_mv | AT bernayıldırım midkinemdkincanceranddrugresistancefrominflammationtotherapy AT kudretkulak midkinemdkincanceranddrugresistancefrominflammationtotherapy AT ayhanbilir midkinemdkincanceranddrugresistancefrominflammationtotherapy |